JP2012515195A5 - - Google Patents

Download PDF

Info

Publication number
JP2012515195A5
JP2012515195A5 JP2011545788A JP2011545788A JP2012515195A5 JP 2012515195 A5 JP2012515195 A5 JP 2012515195A5 JP 2011545788 A JP2011545788 A JP 2011545788A JP 2011545788 A JP2011545788 A JP 2011545788A JP 2012515195 A5 JP2012515195 A5 JP 2012515195A5
Authority
JP
Japan
Prior art keywords
compound
composition
deoxyactagardine
composition according
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011545788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515195A (ja
JP5719312B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2010/000042 external-priority patent/WO2010082018A1/en
Publication of JP2012515195A publication Critical patent/JP2012515195A/ja
Publication of JP2012515195A5 publication Critical patent/JP2012515195A5/ja
Application granted granted Critical
Publication of JP5719312B2 publication Critical patent/JP5719312B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011545788A 2009-01-14 2010-01-12 デオキシアクタガルジン誘導体 Expired - Fee Related JP5719312B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14449009P 2009-01-14 2009-01-14
US61/144,490 2009-01-14
PCT/GB2010/000042 WO2010082018A1 (en) 2009-01-14 2010-01-12 Deoxyactagardine derivatives

Publications (3)

Publication Number Publication Date
JP2012515195A JP2012515195A (ja) 2012-07-05
JP2012515195A5 true JP2012515195A5 (https=) 2013-03-07
JP5719312B2 JP5719312B2 (ja) 2015-05-13

Family

ID=42110329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011545788A Expired - Fee Related JP5719312B2 (ja) 2009-01-14 2010-01-12 デオキシアクタガルジン誘導体

Country Status (22)

Country Link
US (2) US8283371B2 (https=)
EP (1) EP2387580B1 (https=)
JP (1) JP5719312B2 (https=)
KR (1) KR20110119699A (https=)
CN (1) CN102348718B (https=)
AU (1) AU2010205472B2 (https=)
CA (1) CA2749278A1 (https=)
DK (1) DK2387580T3 (https=)
EA (1) EA021683B1 (https=)
ES (1) ES2520165T3 (https=)
HR (1) HRP20141084T1 (https=)
IL (1) IL213927A0 (https=)
MX (1) MX2011007313A (https=)
NZ (1) NZ594011A (https=)
PL (1) PL2387580T3 (https=)
PT (1) PT2387580E (https=)
RS (1) RS53586B1 (https=)
SG (1) SG172944A1 (https=)
SI (1) SI2387580T1 (https=)
TW (1) TWI453029B (https=)
WO (1) WO2010082018A1 (https=)
ZA (1) ZA201104991B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
SI2387580T1 (sl) 2009-01-14 2014-11-28 Novacta Biosystems Limited Deoksiaktagardinski derivati
MX2011008043A (es) 2009-02-04 2011-08-17 Novacta Biosystems Ltd Derivados de actagardina.
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013507D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013509D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013508D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201213434D0 (en) 2012-07-27 2012-09-12 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) * 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (https=) 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
EP0700998B1 (en) 1994-09-12 2003-11-26 Aventis Pharma Deutschland GmbH Recombinant mersacidin and a method for production
CN1138560C (zh) 1995-06-23 2004-02-18 Ambi股份有限公司 控制对抗生素耐药的革兰氏阳性细菌的方法和治疗感染的方法
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
US5985823A (en) 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
DE19745583A1 (de) 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
JP2006502713A (ja) 2002-10-10 2006-01-26 モリケム メディシンズ, インコーポレイテッド デュラマイシンをコードする核酸
ES2281808T3 (es) 2003-07-18 2007-10-01 Vicuron Pharmaceuticals, Inc. Antibiotico 107891, sus factores a1 y a2, composiciones y sales farmaceuticamente aceptables y uso del mismo.
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
JP2009509519A (ja) 2005-09-27 2009-03-12 ノヴァクタ バイオシステムズ リミティッド ランチビオティックメルサシジンの変種およびそれらの使用
GB0600928D0 (en) * 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
KR20120038021A (ko) 2006-10-27 2012-04-20 화이자 프로덕츠 인코포레이티드 하이드록시프로필 메틸 셀룰로스 경질 캡슐 및 이의 제조 방법
CA2690267A1 (en) 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
WO2010058238A1 (en) 2008-11-24 2010-05-27 Sentinella Pharmaceuticals, Inc. ("Sentinella") Lantibiotic carboxyamide derivatives with enhanced antibacterial activity
SI2387580T1 (sl) 2009-01-14 2014-11-28 Novacta Biosystems Limited Deoksiaktagardinski derivati
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
MX2011008043A (es) 2009-02-04 2011-08-17 Novacta Biosystems Ltd Derivados de actagardina.

Similar Documents

Publication Publication Date Title
JP2012515195A5 (https=)
US20240116911A1 (en) Ribocil c antibiotics effective for gram-negative pathogens
HU229935B1 (en) Dual action antibiotics
JP2010530881A5 (https=)
JP2006182786A5 (https=)
JP2011526283A5 (https=)
ES2520165T3 (es) Derivados de desoxiactagardina
JP2015505296A5 (https=)
JP2013511540A5 (https=)
JP2020507589A5 (https=)
JP2005523922A5 (https=)
JP2006143751A5 (https=)
JP2011527334A5 (https=)
JP2011509302A5 (https=)
JP2012506870A5 (https=)
JP2013542992A5 (https=)
JP2015521617A5 (https=)
JP2015505301A5 (https=)
US20240190872A1 (en) Fabi inhibitors for gram-negative pathogens
KR20110122139A (ko) 액타가르딘 유도체
JP2023109937A (ja) 3-置換1,2,4-オキサジアゾールの結晶形態
JP2011526286A5 (https=)
WO2011063764A1 (zh) 阿齐沙坦有机胺盐及其制备方法和用途
EP4452967A2 (en) Inhibitors of sars-cov-2
JP2014511897A5 (https=)